DVA

Davita

Healthcare Medical Care Facilities NYSE

About the company

Founded in 1999, DaVita has emerged as a powerhouse in the healthcare industry, specifically in the field of dialysis services. With a presence in over 3,000 facilities worldwide, the majority of which are in the United States, DaVita has solidified its position as the largest provider of dialysis services in the country. This dominance is evident in its market share, which exceeds 35% when measured by both the number of patients and the number of clinics. Dialysis, a life-sustaining treatment for individuals with kidney failure, is a vital service that demands substantial resources, expertise, and infrastructure. DaVita's extensive network of facilities enables them to treat over 240,000 patients globally each year, underscoring their significant contribution to the provision of dialysis services around the world. In the United States, reimbursement for dialysis services primarily comes from government payers, particularly Medicare. Approximately two-thirds of DaVita's sales in the U.S. stem from government reimbursement rates. This reliance on government payers is a testament to the critical role they play in funding healthcare services for individuals with chronic conditions. However, it is worth noting that commercial insurers also contribute to DaVita's revenue stream. Interestingly, despite representing only about 10% of the U.S. patients treated, commercial insurers account for nearly all of the profits generated by DaVita in the U.S. dialysis business. This discrepancy between patient numbers and profits highlights the intricacies of the healthcare reimbursement system in the United States. Commercial insurers often negotiate higher reimbursement rates, which can contribute significantly to a provider's financial success. DaVita's ability to generate substantial profits from commercial insurers can be attributed to several factors. Firstly, commercial insurers typically offer higher reimbursement rates, allowing providers like DaVita to secure more favorable financial terms for the care they deliver. Secondly, patients with commercial insurance often have lower medical complexity, translating into lower treatment costs and higher profit margins. Finally, the competitive landscape in the dialysis industry may also play a role, as DaVita's robust market position allows them to negotiate more advantageous contracts with commercial insurers. Beyond its financial success, DaVita is committed to delivering high-quality care to its patients. In recent years, they have undertaken initiatives to improve patient outcomes and reduce hospitalization rates. These efforts include implementing various clinical programs, enhancing care coordination, and leveraging technology to monitor and manage patient health effectively. DaVita's dedication to patient care extends beyond the confines of their facilities. They actively engage in community outreach, striving to educate and raise awareness about kidney disease and the importance of early detection and treatment. Through collaborations with local organizations and initiatives like free screenings, DaVita seeks to make a positive impact on the overall health of communities they serve. As the demand for dialysis services continues to rise, DaVita is well-positioned to maintain its industry leadership. Their extensive presence, formidable market share, and focus on delivering high-quality care have solidified their reputation as a trusted provider of dialysis services. With their commitment to innovation and improving patient outcomes, DaVita is poised to shape the future of dialysis care, setting new standards for excellence in the industry.

Website: https://www.davita.com

Data updated: June 2, 2026

Sector comparison

We compare this company with the typical (middle) company in the same industry to show how it looks against similar businesses. This is information, not a recommendation.

Healthcare · 1346 peers in sector

Metric DVA Sector median Vs. industry
P/E 18.29 20.10 ↓ Below average
EPS 10.38 USD -1.14 USD ↑ Above average
Dividend yield 0.00% 0.00%
Profit margin 5.65% 0.00% ↑ Above average
ROE 80.98% -58.84% ↑ Above average

Higher and lower here are only a comparison with the typical company in the industry — a higher or lower value on its own does not mean better or worse.

Financial statements & historical data

Income statements, balance sheets, cash flow, earnings and dividend history are available for registered users

Sign up for free

AI Summary

AI-generated company analysis is available for registered users.

Sign up for free

Where does this data come from?

Frequently Asked Questions

What is Davita?
Founded in 1999, DaVita has emerged as a powerhouse in the healthcare industry, specifically in the field of dialysis services. With a presence in over 3,000 facilities worldwide, the majority of which are in the United States, DaVita has solidified its position as the largest provider of dialysis services in the country. This dominance is evident in its market share, which exceeds 35% when measured by both the number of patients and the number of clinics. Dialysis, a life-sustaining treatment for individuals with kidney failure, is a vital service that demands substantial resources, expertise, and infrastructure. DaVita's extensive network of facilities enables them to treat over 240,000 patients globally each year, underscoring their significant contribution to the provision of dialysis services around the world. In the United States, reimbursement for dialysis services primarily comes from government payers, particularly Medicare. Approximately two-thirds of DaVita's sales in the U.S. stem from government reimbursement rates. This reliance on government payers is a testament to the critical role they play in funding healthcare services for individuals with chronic conditions. However, it is worth noting that commercial insurers also contribute to DaVita's revenue stream. Interestingly, despite representing only about 10% of the U.S. patients treated, commercial insurers account for nearly all of the profits generated by DaVita in the U.S. dialysis business. This discrepancy between patient numbers and profits highlights the intricacies of the healthcare reimbursement system in the United States. Commercial insurers often negotiate higher reimbursement rates, which can contribute significantly to a provider's financial success. DaVita's ability to generate substantial profits from commercial insurers can be attributed to several factors. Firstly, commercial insurers typically offer higher reimbursement rates, allowing providers like DaVita to secure more favorable financial terms for the care they deliver. Secondly, patients with commercial insurance often have lower medical complexity, translating into lower treatment costs and higher profit margins. Finally, the competitive landscape in the dialysis industry may also play a role, as DaVita's robust market position allows them to negotiate more advantageous contracts with commercial insurers. Beyond its financial success, DaVita is committed to delivering high-quality care to its patients. In recent years, they have undertaken initiatives to improve patient outcomes and reduce hospitalization rates. These efforts include implementing various clinical programs, enhancing care coordination, and leveraging technology to monitor and manage patient health effectively. DaVita's dedication to patient care extends beyond the confines of their facilities. They actively engage in community outreach, striving to educate and raise awareness about kidney disease and the importance of early detection and treatment. Through collaborations with local organizations and initiatives like free screenings, DaVita seeks to make a positive impact on the overall health of communities they serve. As the demand for dialysis services continues to rise, DaVita is well-positioned to maintain its industry leadership. Their extensive presence, formidable market share, and focus on delivering high-quality care have solidified their reputation as a trusted provider of dialysis services. With their commitment to innovation and improving patient outcomes, DaVita is poised to shape the future of dialysis care, setting new standards for excellence in the industry.
Are Davita shares expensive?
The price-to-earnings (P/E) ratio of Davita is 18.29 — the share price is 18.29 times the annual profit per share. That is lower than the typical company in the same industry (industry median: 20.10). This is information, not a recommendation. (as of 2026-06-02)
How big is Davita?
The market capitalization of Davita — the combined value of all its shares — is 12.18 B USD. The higher the market cap, the larger the company. (as of 2026-06-02)
Does Davita pay dividends?
The dividend yield of Davita is 0.00% — it shows the annual dividend relative to the share price. This is information, not a recommendation. (as of 2026-06-02)
What sector does Davita belong to?
Davita operates in the Healthcare sector, industry: Medical Care Facilities.

What do you gain?

With Ecrumen you gain full control over your investments and assets!

All your assets
Stock market investments, real estate, bonds. Be aware of what you have in your portfolio!
AI at the service of your investments
Analyze and optimize your investments using the latest technologies. Sentiments, analyses, tips, reports. Always with up-to-date data!
A community eager to help
Find a place with people similar to you. Share your opinions, see how others manage their investments. Get help with the problems that bother you!
What do you gain?

Want to stay up to date?

Subscribe to our newsletter to stay up to date with Ecrumena news and market information. No spam, unsubscribe in one click.

For more information, please refer to our terms of use.

0/120